Working… Menu

Randomised Evaluation of COVID-19 Therapy (RECOVERY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04381936
Recruitment Status : Recruiting
First Posted : May 11, 2020
Last Update Posted : May 5, 2021
UK Research and Innovation
National Institute for Health Research, United Kingdom
Bill and Melinda Gates Foundation
Department for International Development, United Kingdom
Health Data Research UK
Medical Research Council Population Health Research Unit
NIHR Clinical Trials Unit Support Funding
NIHR Health Protection Research Unit in Emerging and Zoonotic Infections
Information provided by (Responsible Party):
University of Oxford

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2031
Publications of Results:
RECOVERY Collaborative Group, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. Pre-print medRxiv 2021.02.11.21249258; doi:

Publications automatically indexed to this study by Identifier (NCT Number):